REVIEW article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1525821
This article is part of the Research TopicAdvances in Antigen-Specific Immunotherapies for Autoimmune Disease ManagementView all 12 articles
Acrodermatitis Continua Of Hallopeau ：A Review And Update On Biological And Small Molecule Targeted Immunomodulatory Therapies
Provisionally accepted
- 1Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang Province, China
- 2Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China
- 3Tianjin University of Traditional Chinese Medicine, Tianjin, China
- 4Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, Beijing Municipality, China
- 5First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Nankai District, Tianjin, China
- 6Beijing University of Chinese Medicine, Beijing, Beijing Municipality, China
- 7International Hospital, Peking University, Beijing, Beijing Municipality, China
- 8Hangzhou Medical College, Hangzhou, Zhejiang Province, China
- 9Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine Cultivation for Arthritis Diagnosis and Treatment, Hangzhou, Jiangsu Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Acrodermatitis continua of Hallopeau (ACH) is a rare aseptic pustular dermatosis for which clinical guidelines are lacking and treatment is largely based on case reports. Biologically targeted therapies offer new therapeutic ideas, with TNF antagonists such as adalimumab showing promising efficacy in both adults and children.The IL-17 and IL-23 axes play a key role in the pathogenesis of ACH, and anti-IL-17A and anti-IL-23 antibodies have shown therapeutic efficacy. In addition, new therapies such as IL-36 inhibitors and JAK inhibitors are being explored. Although biologics provide a new direction for ACH treatment, their safety and efficacy still need to be confirmed by largescale clinical studies.
Keywords: Acrodermatitis continua of Hallopeau, Immune targeted therapy, TNF inhibitor, IL-17 inhibitor, JAK inhibitor
Received: 10 Nov 2024; Accepted: 23 Jul 2025.
Copyright: © 2025 Sun, Han, Lin, Wu, Li and Ying. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Chen Li, Beijing University of Chinese Medicine, Beijing, 100029, Beijing Municipality, China
Zhenhua Ying, Zhejiang Provincial People's Hospital, Hangzhou, 310014, Zhejiang Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.